August 18, 2021
LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group on Intellectual Disabilities and Dementia Practices (NTG) in sending comments to federal Medicaid and Medicare regulators, asking them to give thought to the consequences for people with Down syndrome as this new class of Alzheimer’s disease drugs is considered by the single largest payer for health care in the United States.
“We urge CMS to ensure that all application efforts consider neuroatypical adults, such as those with Down syndrome, and work to ensure that the impact, utility and safety of these treatments are given due consideration.” You can read the full statement here:
More information about Aduhelm and the Down syndrome community is available here (from NTG) and here (from LuMind IDSC). See the latest myDSC webinar on advances in DS-AD research, here.
